Evidence map›Paper›PMID 37139585›Full record

ArticleThe Australian and New Zealand journal of psychiatry2023

Why didn't the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder?

Susan L Rossell, Sally E Meikle, Martin L Williams, David J Castle

Open access · hybridAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in The Australian and New Zealand journal of psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Susan L RossellCentre for Mental Health, School of Health Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.ORCID 0000-0002-7415-8252
Sally E MeikleMelbourne School of Psychological Science, The University of Melbourne, Melbourne, VIC, Australia.
Martin L WilliamsCentre for Mental Health, School of Health Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.
David J CastleTasmania Centre for Mental Health Service Innovation, University of Tasmania and Statewide Mental Health Service, Hobart, TAS, Australia.ORCID 0000-0002-3075-1580
St Vincent's Hospital Melbourne · AUSwinburne University of Technology · AUThe University of Melbourne · AUUniversity of Tasmania · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Depressive Disorder, Treatment-ResistantHallucinogensMajor Depressive DisorderAustraliaHumansPsilocybinPsychotherapyHallucinogensPsilocybin

Identifiers

PMID37139585
PMCPMC10291361
OpenAlexW4368356691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.